↓ Skip to main content

Oncotarget

Therapeutic response and side effects of repeated radioligand therapy with 177 Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer

Overview of attention for article published in Oncotarget, February 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

policy
1 policy source
twitter
1 X user
patent
1 patent

Citations

dimensions_citation
228 Dimensions

Readers on

mendeley
155 Mendeley
Title
Therapeutic response and side effects of repeated radioligand therapy with 177 Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
Published in
Oncotarget, February 2016
DOI 10.18632/oncotarget.7245
Pubmed ID
Authors

Hojjat Ahmadzadehfar, Elisabeth Eppard, Stefan Kürpig, Rolf Fimmers, Anna Yordanova, Carl Diedrich Schlenkhoff, Florian Gärtner, Sebastian Rogenhofer, Markus Essler

Abstract

Prostate-specific membrane antigen (PSMA) is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer (PC), making it an optimal target for the treatment of metastasized PC. Radioligand therapy (RLT) with 177Lu-PSMA-DKFZ-617 (Lu-PSMA) is a targeted therapy for metastatic PC. In this study, we retrospectively analyzed the side effects and the response rate of 24 hormone and/or chemorefractory PC patients with a mean age of 75.2 years (range: 64-82) with distant metastases and progressive disease according to the PSA level, who were treated with Lu-PSMA. Median PSA was 522 ng/ml (range: 17-2360). Forty-six cycles of Lu-PSMA were performed. Of the 24 patients, 22 received two cycles. Eight weeks after the first cycle of Lu-PSMA therapy 79.1% experienced a decline in PSA level. Eight weeks after the second cycle of Lu-PSMA therapy 68.2% experienced a decline in PSA relative to the baseline value. Apart from two cases of grade 3 anemia, there was no relevant hemato- or nephrotoxicity (grade 3 or 4). These results confirmed that Lu-PSMA is a safe treatment option for metastatic PC patients and has a low toxicity profile. A positive response to therapy in terms of decline in PSA occurs in about 70% of patients.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 155 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 <1%
Canada 1 <1%
Unknown 153 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 22 14%
Student > Ph. D. Student 19 12%
Student > Master 18 12%
Student > Doctoral Student 13 8%
Other 12 8%
Other 33 21%
Unknown 38 25%
Readers by discipline Count As %
Medicine and Dentistry 54 35%
Pharmacology, Toxicology and Pharmaceutical Science 14 9%
Chemistry 14 9%
Agricultural and Biological Sciences 6 4%
Engineering 5 3%
Other 20 13%
Unknown 42 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2022.
All research outputs
#4,255,667
of 23,153,849 outputs
Outputs from Oncotarget
#1,744
of 14,366 outputs
Outputs of similar age
#75,269
of 400,530 outputs
Outputs of similar age from Oncotarget
#98
of 1,034 outputs
Altmetric has tracked 23,153,849 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 14,366 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 400,530 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 1,034 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.